Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.6% below analysts’ estimates. Its GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Global professional services company Jacobs Solutions (NYSE:J) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.2% year on year to $2.91 billion. Its non-GAAP profit of $1.48 per share was 6.9% above analysts’ consensus estimates.
Health insurance company Clover Health (NASDAQ:CLOV) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its GAAP loss of $0 per share was significantly above analysts’ consensus estimates.
Higher education company Grand Canyon Education (NASDAQ:LOPE) announced better-than-expected revenue in Q1 CY2025, with sales up 5.3% year on year to $289.3 million. The company expects next quarter’s revenue to be around $240.3 million, close to analysts’ estimates. Its GAAP profit of $2.52 per share was 2.9% above analysts’ consensus estimates.
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts’ consensus estimates.
Aerospace and defense company Cadre (NYSE:CDRE) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 5.6% year on year to $130.1 million. The company’s full-year revenue guidance of $633 million at the midpoint came in 5.8% above analysts’ estimates. Its GAAP profit of $0.23 per share was 91.7% above analysts’ consensus estimates.
Residential swimming pool manufacturer Latham (NASDAQ:SWIM) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $111.4 million. The company’s full-year revenue guidance of $550 million at the midpoint came in 2.5% above analysts’ estimates. Its GAAP loss of $0.05 per share was 38.1% above analysts’ consensus estimates.
BCIL, a 100% international equity ETF, has beaten benchmarks with a high-conviction, equal-weight strategy backed by a proprietary quantitative engine.
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per share was significantly below analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Global electronics contract manufacturer Kimball Electronics (NYSE:KE) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 11.9% year on year to $374.6 million. The company expects the full year’s revenue to be around $1.42 billion, close to analysts’ estimates. Its non-GAAP profit of $0.27 per share was 42.1% above analysts’ consensus estimates.
